Methotrexate-related lymphoproliferative disorder of the stomach in a patient with rheumatoid arthritis: a case of disease regression after methotrexate cessation

Clinical Journal of Gastroenterology

Volumn 9, Issue 1, 2016, Pages 17-21

  Ikeda, Kazuki ^a   Nakamura, Takefumi ^a,c   Kinoshita, Takahiro ^b   Fujiwara, Mikio ^a   Uose, Suguru ^a   Someda, Hitoshi ^a   Miyoshi, Takashi ^a   Io, Katsuhiro ^a   Nagai, Ken ichi ^a  

^a KANSAI DENRYOKU HOSPITAL   (Japan)

^b Asahibashi Ichoka Naika Clinic   (Japan)

^c KANSAI ELECTRIC POWER CO   (Japan)

Author keywords

Lymphoproliferative disorder (LPD); Methotrexate (MTX); Rheumatoid arthritis (RA); Stomach

Indexed keywords

CYCLOPHOSPHAMIDE; FLUORODEOXYGLUCOSE F 18; METHOTREXATE; PIRARUBICIN; PREDNISOLONE; RITUXIMAB; SALAZOSULFAPYRIDINE; VINCRISTINE; ANTIRHEUMATIC AGENT;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; CELL PROLIFERATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG WITHDRAWAL; FEMALE; GASTRIC LYMPHOPROLIFERATIVE DISORDER; GASTROINTESTINAL ENDOSCOPY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOLOGY; LARGE CELL LYMPHOMA; LYMPHOID CELL; LYMPHOPROLIFERATIVE DISEASE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; STOMACH BIOPSY; ARTHRITIS, RHEUMATOID; CHEMICALLY INDUCED; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOPROLIFERATIVE DISORDERS; MULTIMODAL IMAGING; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; STOMACH NEOPLASMS; TUMOR REGRESSION; X-RAY COMPUTED TOMOGRAPHY;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOPROLIFERATIVE DISORDERS; METHOTREXATE; MULTIMODAL IMAGING; NEOPLASM REGRESSION, SPONTANEOUS; POSITRON-EMISSION TOMOGRAPHY; STOMACH NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84959075087     PISSN: 18657257     EISSN: 18657265     Source Type: Journal    
DOI: 10.1007/s12328-015-0624-5     Document Type: Article

References (9)

1. Agarwal SK. Core management principles in rheumatoid arthritis to help guide managed care professionals. J Manag Care Phalm. 2011;9(Suppl B):S03–8.
2. Thomas E, Brewster DH, Black RJ, et al. Risk of malignancy among patients with rheumatoid conditions. Int J Cancer. 2000;88:497–502.
3. Swerdlow SH, Campo E, Harris NL, et al. World Health Organization classification of tumours of hematopoietic and lymphoid tissues. 4th ed. Lyon: IARC Press; 2008.
4. Hoshida Y, Xu JX, Fujita S, et al. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol. 2007;34:322–31.
5. Saloum E, Cooper DL, Howe G, et al. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J Clin Oncol. 1996;14:1943–9.
6. Satoh K, Yoshida N, Imaizumi K, et al. Reversible methotrexate-associated lymphoproliferative disorder resembling advanced gastric cancer in a patient with rheumatoid arthritis. Am J Med Sci. 2009;338:334–5.
7. Strobel K, von Hochstetter AR, Exner UG. FDG uptake in a rheumatoid nodule with imaging appearance similar to a malignant soft tissue tumor. Clin Nucl Med. 2009;34:691–2.
8. Ichikawa A, Arakawa F, Kiyasu J, et al. Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression. Hematology. 2013;91:20–8.
9. Daniel M, Knowles MD. Immunodeficiency-associated lymphoproliferative disorders. Mod Pathol. 1999;12:200–17.